Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $8.1600 (-32.84%) ($8.1100 - $9.0500) on Tue. Mar. 5, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.24% (three month average) | RSI | 53 | Latest Price | $8.1600(-32.84%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -5.2% a day on average for past five trading days. | Weekly Trend | ADMS advances 3.9% a week on average for past two weeks. | Market Behavior | Normal for large cap. Value stock sell-off for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) XOP(13%) OIH(12%) XBI(10%) EWI(9%) IBB(9%) | Factors Impacting ADMS price | ADMS will decline at least -2.62% in a week (0% probabilities). BNDX(-11%) UUP(-9%) GLD(-8%) GDX(-8%) GDXJ(-7%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.62% (StdDev 5.24%) | Hourly BBV | 0 () | Intraday Trend | -6.2% | | | |
|
Resistance Level | $10.28 | 5 Day Moving Average | $10.85(-24.79%) | 10 Day Moving Average | $10.98(-25.68%) | 20 Day Moving Average | $10.28(-20.62%) | To recent high | -32.8% | To recent low | 5.3% | Market Cap | $231m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |